Peptide basics
Cosmetic peptides have almost no trials, and that is by regulatory design
On this page
GHK-Cu has one verified registered human trial with 60 participants.
Palmitoyl pentapeptide-4, sold as Matrixyl, has no registered human trial naming it as an intervention.
Acetyl hexapeptide-8, sold as Argireline, has two trials totalling 22 participants.
All three are regulated as cosmetic ingredients rather than drugs, and cosmetics are not required to demonstrate effectiveness before sale.
This page compares the trial record of cosmetic peptides and explains the regulatory reason it is thin. It makes no claim about whether any of them work and gives no usage guidance.
The records
GHK-Cu has one registered trial we verified as administering it, enrolling 60 people. Palmitoyl pentapeptide-4 has none. Acetyl hexapeptide-8 has two, with 22 participants between them.12
Twenty-two people across two studies is not a typo. It is the entire registered human record for one of the most widely sold cosmetic peptides in the world.1
Why the regulatory category decides this
In US law a product's category follows its intended use. Something marketed to cleanse or beautify is a cosmetic. Something marketed to affect the structure or function of the body is a drug, and drugs require pre-market review.3
Cosmetics carry no such requirement to demonstrate effectiveness before sale. So there is no commercial reason to run a large trial, and consequently almost nobody does.3
Attention runs the opposite way again
GHK-Cu draws 20,088 monthly encyclopedia views on the strength of one 60-person trial. Palmitoyl pentapeptide-4 draws 613 with no trial at all. Thymosin alpha-1, with 50 trials and 14,247 participants, draws 55.12
Readership here is tracking consumer marketing, which is exactly what you would expect for ingredients sold in retail skincare.1
What this does and does not imply
It does not imply cosmetic peptides do nothing. Laboratory work exists for all three, and a cosmetic effect on appearance is a modest claim that a trial-grade evidence base was never required to support.3
It does mean that when a skincare peptide is described as clinically proven, the natural question is which clinical study, with how many participants. For these three the honest answers are one study of 60, none, and two studies of 22.12
Common questions
Do manufacturers run their own studies?
Frequently, and those studies are often small, unregistered, and unpublished. They may be perfectly well conducted; they are simply not in the public record where anyone can examine them.
Is a cosmetic ingredient unregulated?
Not unregulated — safety and labelling requirements apply. What does not apply is the requirement to prove effectiveness before sale.
Why does GHK-Cu appear with a copper symbol in its formula?
It is a copper-binding tripeptide, and the copper is part of the complex. Its recorded formula includes copper for that reason.
Sources
- RegulatoryClinicalTrials.gov search — intervention: GHK-CuU.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=GHK-Cu ↗↩ Back to text
- RegulatoryClinicalTrials.gov search — intervention: palmitoyl pentapeptide-4U.S. National Library of Medicine, 2026clinicaltrials.gov/search?intr=palmitoyl+pentapeptide-4 ↗↩ Back to text
- RegulatoryFDA — Cosmetics and US law: how cosmetics differ from drugsU.S. Food and Drug Administration, 2025www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-dru ↗↩ Back to text